CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today thatMatt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday,
To access the live presentation via the internet, please go to the direct conference link at:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=DRRX&item_id=2539284 or to the DURECT Investor Relations tab at www.durect.com.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR™, SABER™, ORADUR™, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All